论文部分内容阅读
[目的]观察EZH2和P27蛋白在前列腺癌组织中的表达,分析两者与前列腺癌的病理分级、临床分期之间的关系,探讨EZH2和P27蛋白在前列腺癌临床诊断和评估预后的意义.[方法]选择自2007年1月至2011年12月间接受手术的前列腺癌30例和前列腺增生17例的病理组织标本.采用免疫组织化学二步法检测前列腺癌及前列腺增生组织中EZH2和P27蛋白的表达情况,分析其与病理分级、临床分级之间的关系.[结果]EZH2蛋白表达:在前列腺癌组中及前列腺增生组中的表达阳性率分别为86.7%(26/30),41.2%(7/17),相比较差异具有统计学意义(P<0.05);在前列腺癌高、中分化组与低分化组之间和高中、低分化临床分期之间差异均具有统计学意义(P<0.05).P27蛋白表达:在前列腺癌组中及前列腺增生组中的表达阳性率分别为40.0%(12/30),76.5%(13/17),相比较差异具有统计学意义(P<0.05);P27蛋白的阳性率与前列腺癌组织的病理分级呈负相关.[结论]EZH2和P27蛋白表达检测对于前列腺癌的诊断、疾病进展及预后的判断具有重要的意义.
[Objective] To observe the expression of EZH2 and P27 protein in prostate cancer and to analyze the relationship between them and the pathological grade and clinical stage of prostate cancer, and to explore the significance of EZH2 and P27 in clinical diagnosis and prognosis of prostate cancer. Methods Thirty cases of prostate cancer and 17 cases of benign prostatic hyperplasia were selected from January 2007 to December 2011. Immunohistochemistry was used to detect the expression of EZH2 and P27 in prostate cancer and benign prostatic hyperplasia The positive expression rates of EZH2 protein in prostate cancer group and benign prostatic hyperplasia group were 86.7% (26/30) and 41.2% (P <0.05). There was significant difference between the high, moderately differentiated and poorly differentiated groups of prostate cancer and the poorly differentiated clinical stage (P <0.05) .P27 protein expression in prostate cancer group and benign prostatic hyperplasia group were 40.0% (12/30), 76.5% (13/17), respectively, with statistical significance (P < 0.05). The positive rate of P27 protein in prostate cancer tissues Pathological grade was negatively correlated. [Conclusion] EZH2 P27 protein expression for detection and diagnosis of prostate cancer, disease progression and prognosis of great significance.